Form 4: Ocular Therapeutix Chief Scientific Officer Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Ocular Therapeutix's Chief Scientific Officer, Jeffrey S. Heier, sold 2,948 shares of common stock to cover tax obligations related to vesting restricted stock units.
Summary
- Jeffrey S. Heier, the Chief Scientific Officer of Ocular Therapeutix, Inc., sold 2,948 shares of common stock on November 25, 2024.
- The sale was executed at a weighted average price of $9.01 per share, with individual transactions ranging from $8.87 to $9.10.
- This transaction was not a discretionary trade but rather a sell-to-cover action to satisfy tax withholding obligations related to the vesting of restricted stock units on November 22, 2024.
- Following the transaction, Heier beneficially owns 269,059 shares of Ocular Therapeutix common stock.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction for tax purposes and does not indicate any positive or negative sentiment about the company's performance or future prospects.
Industry Context
This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.
Comparison to Industry Standards
- Executive stock sales to cover tax obligations are a common practice across the biotechnology and pharmaceutical industries.
- Many companies use restricted stock units as part of their compensation packages, leading to similar sell-to-cover transactions.
- The volume of shares sold is relatively small compared to the total shares owned by the executive, which is typical for these types of transactions.
- Companies like Regeneron, Amgen, and Biogen also see similar transactions from their executives.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine sale by an executive to cover tax obligations.
- The sale does not indicate any change in the executive's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 04/09/2024 | Date the reporting person adopted a durable automatic sale instruction. |
| 11/22/2024 | Date of vesting of restricted stock units that triggered the tax obligations. |
| 11/25/2024 | Date of the stock sale transaction. |
| 11/27/2024 | Date the Form 4 was signed. |
Keywords
Ocular Therapeutix, insider trading, stock sale, Form 4, Jeffrey S. Heier, tax obligations, restricted stock units, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.